ATE473744T1 - Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren - Google Patents
Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatorenInfo
- Publication number
- ATE473744T1 ATE473744T1 AT05771551T AT05771551T ATE473744T1 AT E473744 T1 ATE473744 T1 AT E473744T1 AT 05771551 T AT05771551 T AT 05771551T AT 05771551 T AT05771551 T AT 05771551T AT E473744 T1 ATE473744 T1 AT E473744T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor modulators
- glucocorticoid receptor
- modified pyrimidine
- pyrimidine glucocorticoid
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58501804P | 2004-07-02 | 2004-07-02 | |
PCT/US2005/023675 WO2006014394A1 (en) | 2004-07-02 | 2005-06-29 | Modified pyrimidine glucocorticoid receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE473744T1 true ATE473744T1 (de) | 2010-07-15 |
Family
ID=35311764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05771551T ATE473744T1 (de) | 2004-07-02 | 2005-06-29 | Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren |
Country Status (17)
Country | Link |
---|---|
US (2) | US7576076B2 (de) |
EP (1) | EP1778236B1 (de) |
JP (1) | JP4958774B2 (de) |
KR (1) | KR101210730B1 (de) |
AT (1) | ATE473744T1 (de) |
AU (1) | AU2005270039B2 (de) |
CA (1) | CA2572544C (de) |
CY (1) | CY1110828T1 (de) |
DE (1) | DE602005022319D1 (de) |
DK (1) | DK1778236T3 (de) |
ES (1) | ES2348667T3 (de) |
HK (1) | HK1097768A1 (de) |
IL (1) | IL180508A0 (de) |
NZ (1) | NZ552984A (de) |
PT (1) | PT1778236E (de) |
WO (1) | WO2006014394A1 (de) |
ZA (1) | ZA200700616B (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2559302C (en) * | 2004-03-15 | 2012-06-19 | Takeda Pharmaceutical Company Limited | 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors |
JP2008524331A (ja) * | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
PT1942898E (pt) | 2005-09-14 | 2011-12-20 | Takeda Pharmaceutical | Inibidores da dipeptidilpeptidase para o tratamento da diabetes |
US20100016427A1 (en) * | 2006-08-11 | 2010-01-21 | Taishio Pharmaceutical Co., Ltd. | External preparation comprising prostaglandin derivative |
TWI410422B (zh) * | 2007-01-15 | 2013-10-01 | Mitsubishi Tanabe Pharma Corp | 縮合四氫喹啉衍生物及其醫藥用途 |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
EP2211845B1 (de) * | 2007-10-17 | 2017-02-22 | Laboratoire HRA Pharma | Glucocorticoid-rezeptor-antagonisten wie mifepriston zur behandlung des cushing-syndroms |
CA2742964C (en) * | 2008-11-07 | 2020-07-07 | University Of Sheffield | Medicament and method of diagnosis |
EP2685827B1 (de) * | 2011-03-18 | 2016-02-03 | Corcept Therapeutics, Inc. | Pyrimidin-cyclohexyl-glucocorticoid-rezeptor-modulatoren |
WO2012135274A1 (en) * | 2011-03-31 | 2012-10-04 | Pop Test Cortisol Llc | Prevention of infection |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
KR101686872B1 (ko) * | 2014-08-25 | 2016-12-20 | 부산대학교 산학협력단 | Tlr4에 lps와의 경쟁적 결합을 통한 항산화 및 항염증 활성을 갖는 신규 화합물 및 이의 의학적 용도 |
WO2016032127A2 (ko) * | 2014-08-25 | 2016-03-03 | 부산대학교 산학협력단 | Tlr4에 lps와의 경쟁적 결합을 통한 항산화 및 항염증 활성을 갖는 신규 화합물 및 이의 의학적 용도 |
US10183949B2 (en) | 2014-08-29 | 2019-01-22 | The University Of Tokyo | Pyrimidinone derivative having autotaxin-inhibitory activity |
KR20180052120A (ko) | 2015-08-13 | 2018-05-17 | 코어셉트 쎄라퓨틱스, 잉크. | Acth-의존성 쿠싱 증후군을 감별 진단하는 방법 |
WO2017127448A1 (en) | 2016-01-19 | 2017-07-27 | Corcept Therapeutics, Inc. | Differential diagnosis of ectopic cushing's syndrome |
WO2018183947A1 (en) | 2017-03-31 | 2018-10-04 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
US11542248B2 (en) * | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
MX2020012831A (es) * | 2018-06-04 | 2021-04-28 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoide de pirimidina ciclohexenilo. |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
CN117281790A (zh) | 2018-12-19 | 2023-12-26 | 科塞普特治疗公司 | 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂 |
KR20220113767A (ko) * | 2019-12-11 | 2022-08-16 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 미리코릴란트로 항정신병약-유도 체중 증가를 치료하는 방법 |
CN115551836A (zh) | 2020-05-06 | 2022-12-30 | 科赛普特治疗公司 | 嘧啶环己基糖皮质激素受体调节剂的多晶型物 |
US11827608B2 (en) | 2020-12-21 | 2023-11-28 | Corcept Therapeutics Incorporated | Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3011809A1 (de) * | 1980-03-27 | 1981-10-01 | Cassella Ag, 6000 Frankfurt | Pyrimidyl-chinazoline, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und ihre verwendung |
US5008267A (en) | 1988-10-29 | 1991-04-16 | Mitsui Toatsu Chemicals, Incorporated | Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same |
JPH06128238A (ja) | 1992-10-20 | 1994-05-10 | Mitsui Toatsu Chem Inc | 新規ピリミジンジオン誘導体 |
EP0722732A1 (de) | 1995-01-24 | 1996-07-24 | Mitsui Toatsu Chemicals, Inc. | Pyrimidindionderivate enthaltendes Arzneimittel mit verlängerter Wirkstoffabgabe |
JPH1017555A (ja) | 1996-07-02 | 1998-01-20 | Mitsui Petrochem Ind Ltd | 6−アミノ−5−メチルウラシル誘導体 |
EP1201660B1 (de) * | 2000-10-30 | 2005-08-31 | Pfizer Products Inc. | Glucocorticoid Rezeptor Modulatoren |
GB0029100D0 (en) * | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
JP2003017555A (ja) | 2001-06-29 | 2003-01-17 | Hitachi Ltd | 半導体集積回路装置およびその製造方法 |
US20030232813A1 (en) | 2002-04-10 | 2003-12-18 | Orchid Chemicals & Pharmaceuticals Limited | Novel amino substituted pyrimidinone derivatives |
-
2005
- 2005-06-29 PT PT05771551T patent/PT1778236E/pt unknown
- 2005-06-29 AU AU2005270039A patent/AU2005270039B2/en not_active Ceased
- 2005-06-29 WO PCT/US2005/023675 patent/WO2006014394A1/en active Application Filing
- 2005-06-29 DK DK05771551.8T patent/DK1778236T3/da active
- 2005-06-29 NZ NZ552984A patent/NZ552984A/en not_active IP Right Cessation
- 2005-06-29 AT AT05771551T patent/ATE473744T1/de active
- 2005-06-29 DE DE602005022319T patent/DE602005022319D1/de active Active
- 2005-06-29 KR KR1020077002664A patent/KR101210730B1/ko not_active IP Right Cessation
- 2005-06-29 EP EP05771551A patent/EP1778236B1/de not_active Not-in-force
- 2005-06-29 CA CA2572544A patent/CA2572544C/en not_active Expired - Fee Related
- 2005-06-29 US US11/174,096 patent/US7576076B2/en active Active
- 2005-06-29 ES ES05771551T patent/ES2348667T3/es active Active
- 2005-06-29 JP JP2007519511A patent/JP4958774B2/ja not_active Expired - Fee Related
-
2007
- 2007-01-02 IL IL180508A patent/IL180508A0/en not_active IP Right Cessation
- 2007-01-22 ZA ZA200700616A patent/ZA200700616B/xx unknown
- 2007-05-17 HK HK07105207.1A patent/HK1097768A1/xx unknown
-
2009
- 2009-07-08 US US12/499,753 patent/US8173664B2/en active Active
-
2010
- 2010-10-11 CY CY20101100904T patent/CY1110828T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005270039A1 (en) | 2006-02-09 |
US20090275600A1 (en) | 2009-11-05 |
ZA200700616B (en) | 2008-09-25 |
JP4958774B2 (ja) | 2012-06-20 |
US20060025405A1 (en) | 2006-02-02 |
US7576076B2 (en) | 2009-08-18 |
JP2008505117A (ja) | 2008-02-21 |
NZ552984A (en) | 2010-06-25 |
KR101210730B1 (ko) | 2012-12-10 |
ES2348667T3 (es) | 2010-12-10 |
DE602005022319D1 (de) | 2010-08-26 |
CY1110828T1 (el) | 2015-06-10 |
PT1778236E (pt) | 2010-10-19 |
US8173664B2 (en) | 2012-05-08 |
DK1778236T3 (da) | 2010-10-25 |
KR20070039579A (ko) | 2007-04-12 |
WO2006014394A1 (en) | 2006-02-09 |
EP1778236B1 (de) | 2010-07-14 |
CA2572544C (en) | 2013-02-26 |
IL180508A0 (en) | 2007-06-03 |
EP1778236A1 (de) | 2007-05-02 |
HK1097768A1 (en) | 2007-07-06 |
CA2572544A1 (en) | 2006-02-09 |
AU2005270039B2 (en) | 2011-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE473744T1 (de) | Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren | |
DK1761497T3 (da) | Azadecalinglucocorticoidreceptormodulatorer | |
TNSN07196A1 (en) | Potentiators of glutamate receptors | |
TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
MX341370B (es) | Antagonistas anti - beta7 humanizados y usos para los mismos. | |
DK1773885T3 (da) | Humaniserede anti-c-met-antagonister | |
CY1108621T1 (el) | Ενωσεις συγχωνευμενου δακτυλιου αζαδεκαλινης ως ρυθμιστες υποδοχεα γλυκοκορτικοειδων | |
EP2101772A4 (de) | Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon | |
TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same | |
EA200601267A1 (ru) | Модуляторы рецепторов андрогена | |
NO20074277L (no) | Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer | |
NO20073369L (no) | Modulatorer av muskarinreseptorer | |
MX2008000874A (es) | Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina. | |
TW200716130A (en) | Purified form of tanaproget | |
ATE417816T1 (de) | Anilinohexafluoroisopropanol verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1778236 Country of ref document: EP |